DE69232650T2 - Vakzine gegen katzenleukämievirus - Google Patents

Vakzine gegen katzenleukämievirus

Info

Publication number
DE69232650T2
DE69232650T2 DE69232650T DE69232650T DE69232650T2 DE 69232650 T2 DE69232650 T2 DE 69232650T2 DE 69232650 T DE69232650 T DE 69232650T DE 69232650 T DE69232650 T DE 69232650T DE 69232650 T2 DE69232650 T2 DE 69232650T2
Authority
DE
Germany
Prior art keywords
leukemia virus
vaccine against
against cat
cat leukemia
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232650T
Other languages
English (en)
Other versions
DE69232650D1 (de
Inventor
Calvert Wardley
Ray Thomsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69232650D1 publication Critical patent/DE69232650D1/de
Application granted granted Critical
Publication of DE69232650T2 publication Critical patent/DE69232650T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69232650T 1991-11-08 1992-10-08 Vakzine gegen katzenleukämievirus Expired - Fee Related DE69232650T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78916391A 1991-11-08 1991-11-08
US85706492A 1992-03-25 1992-03-25
PCT/US1992/008427 WO1993009238A1 (en) 1991-11-08 1992-10-08 Feline leukemia virus vaccines

Publications (2)

Publication Number Publication Date
DE69232650D1 DE69232650D1 (de) 2002-07-25
DE69232650T2 true DE69232650T2 (de) 2002-11-28

Family

ID=27120881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232650T Expired - Fee Related DE69232650T2 (de) 1991-11-08 1992-10-08 Vakzine gegen katzenleukämievirus

Country Status (12)

Country Link
EP (2) EP0611397B1 (de)
JP (1) JP2852395B2 (de)
KR (1) KR100265393B1 (de)
AT (1) ATE219520T1 (de)
AU (2) AU672372B2 (de)
CA (1) CA2120137C (de)
DE (1) DE69232650T2 (de)
DK (1) DK0611397T3 (de)
ES (1) ES2177530T3 (de)
LV (1) LV13060B (de)
MX (1) MX9206018A (de)
WO (1) WO1993009238A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090379A (en) * 1992-04-29 2000-07-18 Boyce Thompson Institute For Plant Research, Inc. Stable pre-occluded virus particle for use in recombinant protein production and pesticides
ES2203617T3 (es) * 1992-04-29 2004-04-16 Boyce Thompson Institute For Plant Research, Inc. Infeccion oral de larvas de insectos con particulas de baculovirus pre-ocluidos.
US5593669A (en) * 1992-04-29 1997-01-14 Boyce Thompson Institute For Plant Research, Inc. Stable pre-occluded virus particle
FR2715664B1 (fr) * 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
KR20190062084A (ko) 2017-11-28 2019-06-05 주식회사 제트바이오텍 고양이 백혈병 바이러스 검출용 프라이머 및 이를 포함한 진단 키트
CN109679970B (zh) * 2018-11-20 2020-12-08 杭州贤至生物科技有限公司 猫疱疹i型病毒快速检测的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173997A1 (de) * 1984-09-06 1986-03-12 Chiron Corporation Katzenleukämievirusproteinimpfstoffe und ihre Herstellung
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
GB8523999D0 (en) * 1985-09-30 1985-11-06 Jabay Ltd Injection of liquid into meat
JP2656521B2 (ja) * 1986-05-30 1997-09-24 ケンブリッジ・バイオサイエンス・コーポレーション ネコ白血病ウイルス抗原の製造法と用途
AU4194089A (en) * 1988-08-08 1990-03-05 Cetus Corporation Methods for isolating herpes virus thymidine kinase-encoding dna
CA2068713A1 (en) * 1989-11-20 1991-05-21 Omar K. Haffar Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens

Also Published As

Publication number Publication date
AU2892392A (en) 1993-06-07
DK0611397T3 (da) 2002-10-07
AU4213496A (en) 1996-04-26
LV13060B (en) 2003-12-20
DE69232650D1 (de) 2002-07-25
MX9206018A (es) 1993-05-01
ATE219520T1 (de) 2002-07-15
CA2120137C (en) 2004-05-04
AU672372B2 (en) 1996-10-03
EP1136562A3 (de) 2003-06-25
JP2852395B2 (ja) 1999-02-03
EP1136562A2 (de) 2001-09-26
KR100265393B1 (ko) 2000-10-02
EP0611397B1 (de) 2002-06-19
JPH06510910A (ja) 1994-12-08
CA2120137A1 (en) 1993-05-13
EP0611397A1 (de) 1994-08-24
ES2177530T3 (es) 2002-12-16
AU689355B2 (en) 1998-03-26
WO1993009238A1 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
FI923443A0 (fi) Foereningar och foerfarande foer inhibering av hiv och liknande virus.
ATE241014T2 (de) Hiv-2 varianten
CY2007016I1 (el) Εμβολιο ιου θηλωματος
ES2045475T3 (es) Rna del genoma del virus de la hepatitis no-a, no-b, cdna y proteina del antigeno del virus.
DE69232650D1 (de) Vakzine gegen katzenleukämievirus
FI950567A0 (fi) Hepatitis A-virusrokote
DE69101683D1 (de) Rekombinantes Mareks-Krankheitsvirus.
FI930051A0 (fi) 4,13-dioxabicyklo(8.2.1)tridecenonderivat sam foerfarande och mellanprodukt foer deras framstaellning
DE68910577T2 (de) Mittel gegen den AIDS-Virus.
DE69021761T2 (de) Impfstoff gegen Tinea.
FI895788A0 (fi) Foerfarande och aemnen foer mikrobiologisk biokonversion av toluen och andra fenylfoereningar.
ES2104752T3 (es) Materiales dentales a base de (met)acrilatos.
ITRM910546A0 (it) Epitopi della proteina env del virus dell'epatite c
DE58904845D1 (de) Zahnaerztliches saughandstueck.
ITRM920295A1 (it) Trasloelevatore.
KR950700933A (ko) 사람 면역결핍 바이러스(HIV) 표면 당단백질로부터 유래된 합성 폴리펩타이드(Synthetic polypeptides derived from the HIV envelope glycoprotein)
FI934777A0 (fi) Multipel hepatitis b virus ytproteiner som bildar partiklar
DE69020848D1 (de) Impfstoff gegen IBV.
NO900442D0 (no) Vaksineblanding.
MX9206973A (es) Vacuna a base de virus del herpes bovino modificado tipo 1.
DE69014974T2 (de) Impfstoff gegen Hundecoronavirus.
NO901959D0 (no) Malaria-vaksine.
PT85845A (de) Vaccine gegen hepatitis a
ITPG910012V0 (it) Bavaglio monouso
FI916113A0 (fi) Foerfarande och anordning foer att foergoera i luft foerekommande virus, bakterier, svamp o.dyl. mikrober.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee